Prevalencija enterokoka rezistentnih na vankomicin (VRE) u Etiopiji: sistematski pregled i meta-analiza.
BMC infectious diseases
Sažetak istraživanja
Pozadina Pojava enterokoka rezistentnih na vankomicin (VRE) predstavlja veliki javnozdravstveni problem otkako je prvi put prijavljen. Iako se rastuće stope VRE infekcija bilježe i drugdje u svijetu; u Etiopiji postoje ograničeni nacionalni objedinjeni podaci. Stoga je cilj ove studije bio da se procijeni objedinjena prevalencija VRE i profila antimikrobne rezistencije enterokoka u Etiopiji.
Metode Pretraživanje literature obavljeno je u PubMed-u, EMBASE-u, Google scholar-u, African Journals online (AJOL) i spremištu Univerziteta Adis Abeba prema smjernicama Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Uključene su i objavljene i neobjavljene studije koje izvještavaju o prevalenciji VRE do 30. juna 2019. godine. Podaci su ekstrahovani koristeći Microsoft Excel i kopirani u Comprehensive Meta-analysis (CMA 2.0) za analizu. Objedinjena procjena VRE je izračunata korištenjem modela slučajnih efekata i 95% CI. Nivo heterogenosti je procijenjen korištenjem Cochran-ovih Q i I 2 testova. Pristranost publikacije je provjerena vizualnom inspekcijom dijagrama lijevka i Beggovim i/ili Eggerovim testom.
Rezultati Dvadeset studija je ispunilo kriterijume podobnosti i sa relevantnim podacima. U analizu je uključeno ukupno 831 enterokoka i 71 izolat VRE. Zbirna prevalencija VRE bila je 14,8% (95% CI; 8,7-24,3; I 2 = 74,05%; P
Zaključak Prevalencija VRE i enterokoka rezistentnih na lijekove je u porastu u Etiopiji. Enterokokni izolati pokazali su rezistenciju na jedan ili više lijekova koji su često rezistentni na različite lijekove ili iste lijekove koji se propisuju na isti lijek. Takođe su pronađeni enterokoki, ali je pojava rezistencije na daptomicin i linezolid alarm za traženje novih načina za liječenje i kontrolu VRE infekcija.
Prikaži originalni naslov i sažetak na engleskom
Prevalence of Vancomycin resistant enterococci (VRE) in Ethiopia: a systematic review and meta-analysis.
Background The emergence of Vancomycin resistant enterococci (VRE) poses a major public health problem since it was first reported. Although the rising rates of VRE infections are being reported elsewhere in the worldwide; there is limited national pooled data in Ethiopia. Therefore, this study was aimed to estimate the pooled prevalence of VRE and antimicrobial resistance profiles of enterococci in Ethiopia.
Methods Literature search was done at PubMed, EMBASE, Google scholar, African Journals online (AJOL) and Addis Ababa University repository following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Both published and unpublished studies reporting the prevalence of VRE until June 30, 2019 were included. Data were extracted using Microsoft Excel and copied to Comprehensive Meta-analysis (CMA 2.0) for analysis. Pooled estimate of VRE was computed using the random effects model and the 95% CIs. The level of heterogeneity was assessed using Cochran's Q and I 2 tests. Publication bias was checked by visual inspection of funnel plots and Begg's and/or Egger's test.
Results Twenty studies fulfilled the eligibility criteria and found with relevant data. A total of 831 enterococci and 71 VRE isolates were included in the analysis. The pooled prevalence of VRE was 14.8% (95% CI; 8.7-24.3; I 2 = 74.05%; P
Conclusion The prevalence of VRE and drug resistant enterococci are on the rise in Ethiopia. Enterococcal isolates showed resistance to one or more of the commonly prescribed drugs in different or the same drug lines. Multidrug resistant (MDR) enterococci were also found. Although the rates were low, the emergence of resistance to Daptomycin and Linezolid is an alarm for searching new ways for the treatment and control of VRE infections. Adherence to antimicrobial stewardship, comprehensive testing and ongoing monitoring of VRE infections in the health care settings are required.
Izvorni podaci
- DOI
- 10.1186/s12879-020-4833-2
- PMID
- 32046668
- PMCID
- PMC7014939
- Provjereno
- 2026-07-26
Naslov i sažetak prevedeni su automatski i prijevod može sadržavati netačnosti ili neprecizne stručne izraze. Za sve detalje, citiranje i medicinsko tumačenje pregledajte originalnu englesku verziju članka. Ne donosite zdravstvene odluke samo na osnovu ovog prijevoda.
Pregledaj originalni članak na engleskom